End-of-day quote
Other stock markets
|
||
- USD | 0.00% |
Nov. 03 | Covance : Dow, S&P 500 close slightly lower; semis boost Nasdaq | RE |
Nov. 03 | Covance : LabCorp to pay $6.1 billion for drug trial company Covance | RE |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Corporate Officer/Principal | - | 23-03-05 | |
Hong Gang Bi
PRN | Corporate Officer/Principal | - | 07-07-31 |
Corporate Officer/Principal | 63 | 12-06-17 | |
Thomas G. Turi
PRN | Corporate Officer/Principal | - | 08-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Eisenberg
BRD | Director/Board Member | 62 | 15-02-18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 82,842,141 | 56,052,052 ( 67.66 %) | 25,882,990 ( 31.24 %) | 67.66 % |
Company contact information
Labcorp Drug Development, Inc.
206 Carnegie Center
08540-6233, Princeton
+336-584-5171
http://www.covance.comSector
1st Jan change | Capi. | |
---|---|---|
+9.72% | 46B | |
+35.14% | 39.85B | |
+4.84% | 39.76B | |
-9.43% | 28.16B | |
+17.47% | 27.62B | |
-22.99% | 18.8B | |
+10.88% | 13.3B | |
+27.53% | 12.2B | |
-6.84% | 11.4B |
- Stock
- Equities
- Stock Covance Inc. - Nyse
- Company Covance Inc.